Gilead Sciences

Gilead and Kites exhibit booth at ASH 2025

Gilead's $2.2B Ouro buy delivers TCE, new purpose for Galapagos

Gilead is paying $1.68 billion for a T-cell engager company via a front-loaded deal that could also give new meaning to its aimless partner Galapagos.

James Waldron Mar 24, 2026 3:34am

Gilead turns down Assembly's ph. 1-stage HBV antiviral

Mar 20, 2026 5:14am

Glowing puzzle piece fitting into puzzle

Gilead inks $8B Arcellx buyout to steer CAR-T into J&J showdown

Feb 23, 2026 7:30am

Gilead pens $1.5B Genhouse deal for synthetic lethal therapy

Feb 16, 2026 2:00pm

JPM26, Day 3: Hundreds attend Biotech CEO Sisterhood meetup

Jan 14, 2026 3:34pm

Gilead Sciences Women HIV Movement campaign

JPM26: Gilead eyes new deals from a 'position of strength'

Jan 14, 2026 3:30am